ScripIt is well known that the pharmaceutical industry is unpredictable. Both drug developers themselves and the brokers covering them must do their best to try and predict the performance of their assets
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. New Vertex/CRISPR Pact Centers On Gene-
Pink SheetOn the surface, the US Food and Drug Administration’s Office of Prescription Drug Promotion seems to have had a quiet year in 2021 issuing just six enforcement letters and initiating only three resear
HBW InsightShould Robert Califf gain a second term as FDA commissioner, he likely will find that many of the issues demanding attention remain the same as when he left the agency five years ago, even though the